BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sodeifian F, Seyedalhosseini ZS, Kian N, Eftekhari M, Najari S, Mirsaeidi M, Farsi Y, Nasiri MJ. Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review. Front Med (Lausanne) 2021;8:731436. [PMID: 34616757 DOI: 10.3389/fmed.2021.731436] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Almutairi AO, El-Readi MZ, Althubiti M, Alhindi YZ, Ayoub N, Alzahrani AR, Al-Ghamdi SS, Eid SY. Liver Injury in Favipiravir-Treated COVID-19 Patients: Retrospective Single-Center Cohort Study. Trop Med Infect Dis 2023;8. [PMID: 36828545 DOI: 10.3390/tropicalmed8020129] [Reference Citation Analysis]
2 Ippolito D, Maino C, Vernuccio F, Cannella R, Inchingolo R, Dezio M, Faletti R, Bonaffini PA, Gatti M, Sironi S. Liver involvement in patients with COVID-19 infection: A comprehensive overview of diagnostic imaging features. World J Gastroenterol 2023; 29(5): 834-850 [DOI: 10.3748/wjg.v29.i5.834] [Reference Citation Analysis]
3 Milionis C, Ilias I, Koukkou E. Liver function in transgender persons: Challenges in the COVID-19 era. World J Clin Cases 2023; 11(2): 299-307 [PMID: 36686345 DOI: 10.12998/wjcc.v11.i2.299] [Reference Citation Analysis]
4 Naeem M, Bano N, Manzoor S, Ahmad A, Munawar N, Razak SIA, Lee TY, Devaraj S, Hazafa A. Pathogenetic Mechanisms of Liver-Associated Injuries, Management, and Current Challenges in COVID-19 Patients. Biomolecules 2023;13. [PMID: 36671484 DOI: 10.3390/biom13010099] [Reference Citation Analysis]
5 Sainz-Gil M, Merino Kolly N, Velasco-González V, Verde Rello Z, Fernandez-Araque AM, Sanz Fadrique R, Martín Arias LH. Hydroxychloroquine safety in Covid-19 vs non-Covid-19 patients: analysis of differences and potential interactions. Expert Opin Drug Saf 2023;22:71-9. [PMID: 35574687 DOI: 10.1080/14740338.2022.2078303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Choaib A, Issa E, El Choueiry F, Eldin JN, Shbaklo K, Alhajj M, Sawaya RT, Assi G, Nader M, Chatila R, Faour WH. SARS-CoV-2-mediated liver injury: pathophysiology and mechanisms of disease. Inflamm Res 2023;72:301-12. [PMID: 36539655 DOI: 10.1007/s00011-022-01683-y] [Reference Citation Analysis]
7 Mendes GMM, Do Nascimento IJB, Marazzi-Diniz PH, Da Silveira IB, Itaborahy MF, Viana LE, Silva FA, Santana MF, Pinto RA, Dutra BG, Lacerda MVG, Araujo SA, Wanderley D, Vidigal PV, Diniz PH, Verano-Braga T, Santos RA, Leite MF. The des-Arg(9)-bradykinin/B1R axis: Hepatic damage in COVID-19. Front Physiol 2022;13:1080837. [PMID: 36601349 DOI: 10.3389/fphys.2022.1080837] [Reference Citation Analysis]
8 Karlafti E, Paramythiotis D, Pantazi K, Georgakopoulou VE, Kaiafa G, Papalexis P, Protopapas AA, Ztriva E, Fyntanidou V, Savopoulos C. Drug-Induced Liver Injury in Hospitalized Patients during SARS-CoV-2 Infection. Medicina (Kaunas) 2022;58. [PMID: 36557050 DOI: 10.3390/medicina58121848] [Reference Citation Analysis]
9 Casalini G, Giacomelli A, Antinori S. Liver tests abnormalities with licensed antiviral drugs for COVID-19: a narrative review. Expert Opin Drug Saf 2022;21:1483-94. [PMID: 36597859 DOI: 10.1080/14740338.2022.2160446] [Reference Citation Analysis]
10 Hanif FM, Majid Z, Ahmed S, Luck NH, Mubarak M. Hepatic manifestations of coronavirus disease 2019 infection: Clinical and laboratory perspective. World J Virol 2022; 11(6): 453-466 [DOI: 10.5501/wjv.v11.i6.453] [Reference Citation Analysis]
11 Akbal-dagistan O, Sevim M, Sen LS, Basarir NS, Culha M, Erturk A, Fael H, Kaptan E, Sancar S, Mulazimoglu Durmusoglu L, Yegen BC, Yildiz-pekoz A. Pulmonary Delivery of Favipiravir in Rats Reaches High Local Concentrations without Causing Oxidative Lung Injury or Systemic Side Effects. Pharmaceutics 2022;14:2375. [DOI: 10.3390/pharmaceutics14112375] [Reference Citation Analysis]
12 Naseralallah LM, Aboujabal BA, Geryo NM, Al Boinin A, Al Hattab F, Akbar R, Umer W, Abdul Jabbar L, Danjuma MI. The determination of causality of drug induced liver injury in patients with COVID-19 clinical syndrome. PLoS ONE 2022;17:e0268705. [DOI: 10.1371/journal.pone.0268705] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Kumar S, Singla B, Singh AK, Thomas-gooch SM, Zhi K, Singh UP. Hepatic, Extrahepatic and Extracellular Vesicle Cytochrome P450 2E1 in Alcohol and Acetaminophen-Mediated Adverse Interactions and Potential Treatment Options. Cells 2022;11:2620. [DOI: 10.3390/cells11172620] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Huang J, Zhang Z, Hao C, Qiu Y, Tan R, Liu J, Wang X, Yang W, Qu H. Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor. Front Pharmacol 2022;13:804189. [DOI: 10.3389/fphar.2022.804189] [Reference Citation Analysis]
15 Aydin N, Yildiz P, Cansu DÜ, Gündogdu E, Mutluay R, Yorulmaz G, Tekin MS, Kocaturk E, Alatas IÖ, Kartal ED, Erben N, Durmaz G, Kasifoglu N, Us T, Sahin G, Bal C, Yilmaz S, Korkmaz C. Investigation of the relationship of CO-RADS and CT patterns with laboratory parameters in COVID-19 patients and a new perspective on the total CT scoring system. BMC Med Imaging 2022;22:128. [PMID: 35858851 DOI: 10.1186/s12880-022-00857-8] [Reference Citation Analysis]
16 Teschke R, Méndez-Sánchez N, Eickhoff A. Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method. Int J Mol Sci 2022;23:4828. [PMID: 35563242 DOI: 10.3390/ijms23094828] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
17 El-megharbel SM, Qahl SH, Alaryani FS, Hamza RZ. Synthesis, Spectroscopic Studies for Five New Mg (II), Fe (III), Cu (II), Zn (II) and Se (IV) Ceftriaxone Antibiotic Drug Complexes and Their Possible Hepatoprotective and Antioxidant Capacities. Antibiotics 2022;11:547. [DOI: 10.3390/antibiotics11050547] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Yip TC, Gill M, Wong GL, Liu K. Management of hepatitis B virus reactivation due to treatment of COVID-19. Hepatol Int 2022. [PMID: 35235148 DOI: 10.1007/s12072-022-10306-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Bayraktutan Z. 4 hidroksi fenilboronik asidin lipopolisakkarit ile indüklenmiş karaciğer hasarı üzerine muhtemel koruyucu etkilerinin incelenmesi. Journal of Boron 2022. [DOI: 10.30728/boron.1057322] [Reference Citation Analysis]